Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
71.6M
-
Shares change
-
+4.07M
-
Total reported value, excl. options
-
$1.86B
-
Value change
-
+$105M
-
Put/Call ratio
-
0.92
-
Number of buys
-
67
-
Number of sells
-
-34
-
Price
-
$25.98
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2019
131 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q4 2019.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71.6M shares
of 226M outstanding shares and own 31.66% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (21.2M shares), Capital Research Global Investors (6.54M shares), BlackRock Inc. (5.02M shares), FMR LLC (4.86M shares), VANGUARD GROUP INC (3.95M shares), Capital International Investors (3.89M shares), Capital World Investors (2.98M shares), VV Manager LLC (2.89M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.47M shares), and REGENTS OF THE UNIVERSITY OF CALIFORNIA (2.35M shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.